Forecast Period | 2025-2029 |
Market Size (2023) | USD 11.76 Billion |
CAGR (2024E-2029F) | 7.01% |
Fastest Growing Segment | Primary Immunodeficiency Diseases |
Largest Market | North America |
Market Size (2029) | USD 17.59 Billion |
Market Overview
Global Intravenous Immunoglobulin Market
was valued at USD 11.76 billion in 2023 and is anticipated to project robust
growth in the forecast period with a CAGR of 7.01% through 2029.
The global
intravenous immunoglobulin (IVIG) market has witnessed substantial growth and
evolution in recent years, driven by factors such as increasing prevalence of
immunodeficiency disorders, rising geriatric population, and advancements in
biotechnology and healthcare infrastructure. IVIG, a blood product derived from
the plasma of healthy donors, contains a high concentration of antibodies and
is administered intravenously to treat various autoimmune and inflammatory
diseases, including primary immunodeficiency disorders, autoimmune
neuropathies, and certain infectious diseases. The market for IVIG is
characterized by a competitive landscape with several key players dominating
the industry, including Grifols, CSL Behring, Takeda Pharmaceutical Company
Limited, and Octapharma AG, among others. These companies are continuously
investing in research and development activities to expand their product
portfolios, enhance manufacturing processes, and improve the efficacy and
safety profiles of their IVIG products. Additionally, strategic collaborations,
mergers, and acquisitions are prevalent strategies adopted by market players to
strengthen their market presence and gain a competitive edge.
Geographically, North America dominates
the global IVIG market, attributed to factors such as high prevalence of
immunodeficiency disorders, well-established healthcare infrastructure, and
favorable reimbursement policies. However, the Asia Pacific region is expected
to witness significant growth during the forecast period, driven by increasing
healthcare expenditure, growing awareness about immunoglobulin therapies, and
rising prevalence of autoimmune and inflammatory diseases. Moreover,
initiatives undertaken by governments and healthcare organizations to improve
access to advanced healthcare services and treatments are expected to further
fuel market growth in the region. Despite the positive growth outlook, the IVIG
market faces certain challenges, including stringent regulatory requirements
for product approval, high costs associated with IVIG therapy, and potential
risks of adverse reactions such as allergic reactions, thrombotic events, and
transmission of infectious agents. Moreover, limited availability of plasma
donors and fluctuations in plasma collection rates pose additional challenges
for manufacturers in ensuring a stable and sustainable supply of IVIG products
to meet market demand. However, ongoing advancements in plasma fractionation
technologies, implementation of stringent quality control measures, and
increasing investment in research and development activities aimed at improving
the safety and efficacy of IVIG therapies are expected to mitigate these
challenges and drive market growth in the coming years.
Key Market Drivers
Growing
Prevalence of Immunodeficiency Disorders
The growing prevalence of
immunodeficiency disorders is a significant factor driving the expansion of the
global intravenous immunoglobulin (IVIG) market. Immunodeficiency disorders
encompass a range of conditions characterized by impaired immune function,
leaving individuals vulnerable to recurrent infections and other complications.
Primary immunodeficiency diseases (PIDs), such as agammaglobulinemia, common
variable immunodeficiency (CVID), and specific antibody deficiency (SAD), are
among the most commonly diagnosed disorders in this category. One of the
primary reasons behind the increasing prevalence of immunodeficiency disorders
is improved diagnostic capabilities and awareness among healthcare
professionals. Advancements in medical technology and screening methods have
enabled more accurate and timely diagnosis of these conditions, leading to a
higher reported prevalence. Growing awareness campaigns and
educational initiatives aimed at healthcare providers and the general public
have contributed to early detection and intervention, further driving up the
number of diagnosed cases.
The rise in immunodeficiency disorders
is also attributed to factors such as genetic predisposition, environmental
factors, and lifestyle changes. Genetic mutations or defects in the immune
system can predispose individuals to immunodeficiency disorders, while
environmental factors such as pollution, exposure to toxins, and infectious
agents may exacerbate immune dysfunction. Moreover, lifestyle factors such as
stress, poor nutrition, and sedentary behavior can compromise immune function,
increasing susceptibility to infections and immune-related disorders.
The increasing prevalence of
immunodeficiency disorders has led to a corresponding rise in the demand for
IVIG therapy. IVIG products, derived from plasma donors, contain a concentrated
mixture of antibodies that can help bolster the immune response in individuals
with immunodeficiency disorders. By supplying exogenous antibodies, IVIG
therapy compensates for the defective or deficient immune system, reducing the
frequency and severity of infections and improving overall quality of life for
patients.
Healthcare providers are increasingly
turning to IVIG therapy as a standard treatment option for managing
immunodeficiency disorders. This growing demand for IVIG products is fueling
market growth, prompting manufacturers to expand production capacities, improve
product quality, and invest in research and development to meet the needs of
patients worldwide. Advancements in biotechnology and
manufacturing processes are driving efficiency gains in IVIG production,
enhancing product safety, and expanding market access, further bolstering the
growth of the global IVIG market.
Expanding
Applications in Autoimmune and Neurological Disorders
The expanding applications of
intravenous immunoglobulin (IVIG) in autoimmune and neurological disorders are
playing a pivotal role in driving the growth of the global IVIG market. IVIG
therapy, traditionally used to treat immunodeficiency disorders, has
increasingly found utility in managing a wide array of autoimmune conditions
and neurological diseases. Autoimmune disorders, characterized by the body's
immune system attacking its own tissues and organs, encompass a diverse range
of conditions such as immune thrombocytopenic purpura (ITP), Guillain-Barré
syndrome (GBS), myasthenia gravis (MG), and systemic lupus erythematosus (SLE),
among others. IVIG therapy has emerged as an effective treatment modality for
these disorders due to its immunomodulatory properties. IVIG contains a high
concentration of antibodies that can modulate immune responses, suppress
inflammatory pathways, and promote immune tolerance, thereby mitigating
autoimmune reactions and reducing disease activity. As a result, healthcare providers
are increasingly prescribing IVIG therapy as a first-line or adjunctive
treatment option for managing autoimmune disorders, driving up the demand for
IVIG products.
In addition to autoimmune disorders,
IVIG therapy is also gaining traction in the field of neurology for the
treatment of various neurological conditions. Chronic inflammatory
demyelinating polyneuropathy (CIDP), multifocal motor neuropathy (MMN), and stiff
person syndrome (SPS) are among the neurological disorders that have shown
positive responses to IVIG treatment. IVIG exerts neuroprotective effects by
modulating immune-mediated neuroinflammation, promoting nerve regeneration, and
restoring neuromuscular function. In CIDP, for example, IVIG therapy has been
shown to improve muscle strength, reduce disability, and prevent disease
relapse, leading to its widespread adoption as a standard treatment option.
The expanding applications of IVIG in
autoimmune and neurological disorders are driving market growth by increasing
the demand for IVIG products across diverse therapeutic indications. As
research continues to uncover new therapeutic targets and treatment strategies,
the potential applications of IVIG therapy are expected to expand further,
creating opportunities for market expansion and innovation. Moreover,
advancements in biotechnology and manufacturing processes are enhancing the
efficacy, safety, and accessibility of IVIG products, further fueling market
growth and meeting the evolving needs of patients with autoimmune and
neurological conditions.
Advancements
in Biotechnology and Manufacturing Processes
Advancements in biotechnology and
manufacturing processes are significant drivers behind the growth of the global
intravenous immunoglobulin (IVIG) market. These advancements have led to
improvements in the quality, safety, and efficacy of IVIG products, thereby
expanding their utilization across various therapeutic applications. One of the key advancements in biotechnology
is the refinement of plasma fractionation techniques. Plasma, the raw material
used in IVIG production, undergoes a complex fractionation process to isolate
and purify immunoglobulins. Innovations in fractionation technology have
enabled manufacturers to produce IVIG products with higher purity levels and
reduced levels of contaminants. This has resulted in safer and more effective
IVIG therapies, minimizing the risk of adverse reactions and ensuring better
patient outcomes.
Advancements in viral
inactivation and pathogen reduction techniques have enhanced the safety profile
of IVIG products. Viral inactivation methods such as solvent-detergent
treatment, pasteurization, and nanofiltration are employed during the
manufacturing process to eliminate potential pathogens and infectious agents
from the plasma-derived products. These advancements have significantly reduced
the risk of transfusion-transmitted infections, making IVIG therapy safer for
patients with compromised immune systems.
Improvements in formulation
technologies have facilitated the development of stabilized liquid IVIG
formulations. Traditionally, IVIG products were available in lyophilized
(freeze-dried) form, requiring reconstitution before administration. However,
liquid IVIG formulations offer several advantages, including convenience in
storage and administration, reduced preparation time, and lower risk of
medication errors. These advancements in formulation technology have improved
patient compliance and healthcare provider convenience, driving the adoption of
IVIG therapy across various clinical settings. Advancements in
manufacturing processes have enabled scalability and increased production
capacities, ensuring a stable and sustainable supply of IVIG products to meet
growing market demand. Automation and optimization of manufacturing workflows
have led to cost efficiencies and reduced production timelines, enabling
manufacturers to scale up production and meet the needs of patients worldwide.
Download Free Sample Report
Key Market Challenges
Regulatory
Hurdles
One of the primary challenges facing the
IVIG market is the stringent regulatory requirements for product approval and
manufacturing. Regulatory agencies impose rigorous standards for the
production, testing, and distribution of IVIG products to ensure their safety,
efficacy, and quality. Compliance with these regulations involves substantial
investments in infrastructure, quality control measures, and documentation,
which can significantly impact manufacturing costs and timelines. Differences in regulatory requirements across regions and countries can create
barriers to market entry and expansion, further complicating the regulatory
landscape for IVIG manufacturers.
High
Cost of IVIG Therapy
The high cost of IVIG therapy poses a
significant barrier to patient access and market growth. IVIG products are
expensive to manufacture due to the complex fractionation process involved in
plasma-derived products, as well as the stringent quality control measures
required to ensure product safety and efficacy. As a result, IVIG therapies are
associated with high treatment costs, placing financial strain on patients,
healthcare systems, and payers. Limited reimbursement coverage for IVIG therapy
in some regions further exacerbates the affordability issue, restricting
patient access to treatment and constraining market demand.
Supply
Chain Vulnerabilities
The global IVIG market relies heavily on
a stable and sustainable supply of plasma, the raw material used in IVIG
production. Plasma collection involves a complex and highly regulated process,
which can be susceptible to disruptions due to factors such as donor
availability, seasonal fluctuations, and regulatory changes. Moreover, the
consolidation of plasma collection centers and the dependence on a limited
number of plasma suppliers can increase the vulnerability of the IVIG supply
chain to supply shortages and disruptions. These supply chain vulnerabilities
pose risks to market stability and continuity of care for patients dependent on
IVIG therapy.
Key Market Trends
Technological
Advancements in IVIG Production
Technological advancements in IVIG
production are playing a pivotal role in boosting the global intravenous
immunoglobulin (IVIG) market. IVIG, derived from plasma donors, is a critical
therapeutic agent used in the treatment of various autoimmune, immunodeficiency,
and neurological disorders. Advancements in IVIG production processes have led
to improved efficiency, quality, and safety of IVIG products, thereby expanding
their availability and utilization across diverse therapeutic indications. One
of the key technological advancements in IVIG production is the refinement of
plasma fractionation techniques. Plasma, the raw material used in IVIG
production, undergoes a complex fractionation process to isolate and purify
immunoglobulins. Innovations in fractionation technology have enabled
manufacturers to produce IVIG products with higher purity levels and reduced
levels of contaminants. This has resulted in safer and more effective IVIG
therapies, minimizing the risk of adverse reactions and ensuring better patient
outcomes.
Advancements in viral
inactivation methods have further enhanced the safety profile of IVIG products.
Viral inactivation techniques such as solvent-detergent treatment,
pasteurization, and nanofiltration are employed during the manufacturing
process to eliminate potential pathogens and infectious agents from the
plasma-derived products. These advancements have significantly reduced the risk
of transfusion-transmitted infections, making IVIG therapy safer for patients
with compromised immune systems. Improvements in formulation
technologies have facilitated the development of stabilized liquid IVIG
formulations. Traditionally, IVIG products were available in lyophilized
(freeze-dried) form, requiring reconstitution before administration. However,
liquid IVIG formulations offer several advantages, including convenience in
storage and administration, reduced preparation time, and lower risk of
medication errors. These advancements in formulation technology have improved
patient compliance and healthcare provider convenience, driving the adoption of
IVIG therapy across various clinical settings.
Advancements in
manufacturing processes have enabled scalability and increased production
capacities, ensuring a stable and sustainable supply of IVIG products to meet
growing market demand. Automation and optimization of manufacturing workflows
have led to cost efficiencies and reduced production timelines, enabling
manufacturers to scale up production and meet the needs of patients worldwide.
Rising
Healthcare Expenditure and Reimbursement Support
Rising healthcare expenditure and
reimbursement support are key factors boosting the global intravenous
immunoglobulin (IVIG) market. IVIG, derived from plasma donors, is a crucial
therapeutic agent used in the treatment of various autoimmune, immunodeficiency,
and neurological disorders. The increasing healthcare expenditure and favorable
reimbursement policies create a conducive environment for market growth in the
IVIG segment, ensuring affordability and accessibility for patients. As
healthcare expenditure continues to rise globally, governments and healthcare
organizations are prioritizing investments in healthcare infrastructure and
expanding access to advanced medical treatments. IVIG therapy, being a
life-saving treatment for many patients with immunodeficiency disorders and
other conditions requiring IVIG, is among the areas benefiting from increased
healthcare spending. Governments are allocating substantial funds to support
research and development initiatives, enhance healthcare delivery systems, and
improve patient access to innovative therapies like IVIG.
Favorable reimbursement
policies play a critical role in driving market adoption and uptake of IVIG
therapy. Reimbursement policies that provide coverage for IVIG treatments
ensure affordability for patients, reducing financial barriers to access.
Health insurance companies and government healthcare programs often provide
reimbursement for IVIG therapy, either partially or in full, depending on the
specific indication and healthcare system regulations. This reimbursement
support incentivizes healthcare providers to prescribe IVIG therapy and
encourages patients to seek treatment, thereby driving market demand.
Collaborations between manufacturers and
healthcare providers are also contributing to the optimization of reimbursement
processes and patient access to IVIG therapy. Manufacturers work closely with
healthcare providers, payers, and patient advocacy groups to streamline
reimbursement procedures, address reimbursement challenges, and optimize
patient access to IVIG products. By improving reimbursement processes and
increasing awareness about reimbursement coverage options, stakeholders in the
IVIG market are enhancing patient access to treatment and driving market
growth.
Segmental Insights
Type Insights
Based on the type, In the Intravenous Immunoglobulin (IVIG) market, Immunoglobulin G (IgG) dominates due to its extensive therapeutic applications and proven efficacy. IgG constitutes the majority of immunoglobulins in plasma, making it crucial for immune response regulation and pathogen neutralization. Its wide-ranging use in treating immunodeficiency disorders, autoimmune diseases, and acute infections underpins its market leadership. IgG's established safety profile, coupled with ongoing advancements in purification and production technologies, enhances its therapeutic potential and accessibility. As a result, IgG remains the cornerstone of IVIG therapies, driving its dominance in the market.
Download Free Sample Report
Regional Insights
North America emerged as the dominant region in the global intravenous immunoglobulin (IVIG) market, commanding the largest market share. This dominance can be attributed to North America's well-established healthcare infrastructure, which comprises advanced medical facilities and a robust regulatory framework. The region is home to numerous prominent pharmaceutical and biotechnology companies specializing in IVIG production, research, and development. Leveraging the region's favorable regulatory environment and access to cutting-edge technology, these companies have developed high-quality IVIG products that meet stringent safety and efficacy standards. Additionally, North America benefits from extensive research and clinical trials conducted in collaboration with leading academic institutions and healthcare organizations, further solidifying its position as a key player in the global IVIG market.
Recent Developments
- In
September 2023, a study published in Blood Cancer Discovery, a journal of
the American Association for Cancer Research (AACR), found that
Intravenous Immunoglobulin (IVIg) decreased the risk of severe infections
by 90% in patients with multiple myeloma who were being treated with an
anti-BCMA bispecific antibody. The use of bispecific antibodies targeting
the BCMA protein is on the rise in the treatment of multiple myeloma, with
two such agents recently receiving approval from the U.S. Food and Drug Administration.
Despite the impressive efficacy of anti-BCMA bispecific antibodies in
heavily pretreated multiple myeloma cases, there has been a notable
incidence of serious, and occasionally fatal, infections among patients
undergoing these therapies.
- In
July 2023, the Food and Drug Administration (FDA) accepted the resubmitted
Biologics License Application (BLA) for GC5107B (immune globulin
intravenous [human]) for patients with primary humoral immunodeficiency
(PI). GC5107B is a liquid solution containing 10% immunoglobulin G (100
mg/mL) for intravenous infusion, produced from pooled human plasma
collected from US donors. The application includes data from an
open-label, single-arm, historically controlled, multicenter Phase 3 study
(ClinicalTrials.gov Identifier: NCT02783482) that evaluated the efficacy
and safety of GC5107B in 49 patients aged 3 to 70 years with a confirmed
diagnosis of PI. The primary endpoint of the study was the incidence of
acute serious bacterial infections (aSBI).
- In
March 2024, the National Institutes of Health (NIH) has announced the
launch of a new clinical trial as part of the Researching COVID to Enhance
Recovery (RECOVER) Initiative, which will evaluate treatment options for
autonomic nervous system dysfunction caused by long COVID. The trial will
focus on three potential treatments for post-COVID POTS. One treatment,
Gamunex-C, is an intravenous immunoglobulin administered through infusion
to deliver antibodies and enhance protection against infection. Another
treatment, ivabradine, is an oral medication that lowers heart rate. In
the first phase of the trial, participants will be randomly assigned to
receive either Gamunex-C, ivabradine, or a placebo. Following this initial
assignment, participants will undergo a second randomization to evaluate
the effectiveness of coordinator-guided, non-drug care as a third
treatment option.
Key Market Players
- Bio
Products Laboratory Ltd.
- Biotest
AG
- China
Biologic Products Holdings Inc.
- CSL Behring
- Grifols SA
- Kedrion SpA
- Shanghai
RAAS Blood Products Co. Ltd
- Octapharma
AG
- Takeda
Pharmaceutical Company Limited
- Baxter International Inc
|
By
Type
|
By
Application
|
By
Region
|
|
|
- Hypogammaglobulinemia
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Primary Immunodeficiency Diseases
- Myasthenia Gravis
- Multifocal Motor Neuropathy
- Other Applications
|
- North America
- Europe
- Asia Pacific
- South America
- Middle East & Africa
|
Report Scope:
In this report, the Global Intravenous
Immunoglobulin Market has been
segmented into the following categories, in addition to the industry trends
which have also been detailed below:
- Intravenous
Immunoglobulin Market, By Type:
o IgG
o IgA
o IgM
o IgE
o IgD
- Intravenous
Immunoglobulin Market, By Application:
o Hypogammaglobulinemia
o Chronic Inflammatory Demyelinating Polyneuropathy
(CIDP)
o Primary Immunodeficiency Diseases
o Myasthenia Gravis
o Multifocal Motor Neuropathy
o Other Applications
- Intravenous
Immunoglobulin Market, By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ France
§ United Kingdom
§ Italy
§ Germany
§ Spain
o Asia-Pacific
§ China
§ India
§ Japan
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
§ Egypt
Competitive Landscape
Company Profiles: Detailed analysis of the major companies
present in the Global Intravenous Immunoglobulin Market.
Available Customizations:
Global Intravenous Immunoglobulin Market report with the given market data, TechSci
Research offers customizations according to a company's specific needs. The
following customization options are available for the report:
Company Information
- Detailed analysis and
profiling of additional market players (up to five).
Global Intravenous Immunoglobulin Market is an upcoming report to be released soon.
If you wish an early delivery of this report or want to confirm the date of release,
please contact us at [email protected]